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Two additional issues merit further 
comment. First, how does SUMO liga-
tion promote TopoII enrichment at CENs? 
A straightforward model is that SUMO-
conjugated forms of TopoII bind receptors 
within CEN chromatin. However, as is the 
case with most SUMO substrates, only a 
small fraction of TopoII is actually sumo-
lyated at any one time. As suggested by 
Dawlaty et al., SUMO modification may 
only be required for an initial step in recruit-
ment, allowing TopoII to remain associated 
with CENs following SUMO deconjuga-
tion (Figure 1). Alternatively, sumolyation 
may promote a different aspect of TopoII 
dynamics, such as enzyme turnover on 
chromatin, which then indirectly facilitates 
CEN targeting through a different pathway. 
Further analysis of the genetic require-
ments for TopoII CEN localization, as well 
as determining if there are factors that bind 
sumolyated TopoII, should help clarify the 
recruitment mechanism.
Second, previous studies have shown 
that TopoII inhibition (or PIASy knockdown) 
during mitosis can activate a preana-
phase checkpoint that exhibits consider-
able overlap with the SAC (Diaz-Martinez 
et al., 2006). The lesion inducing this 
response is unclear, but one idea is that 
a catenate-counting mechanism delays 
anaphase until chromatid entanglements 
fall below a threshold level. In the current 
study, it is notable that failure to com-
pletely decatenate CENs did not appear 
to activate such a checkpoint response. 
Similarly, yeast top2 mutants that exhibit 
a lethal decatenation defect proceed into 
anaphase with normal cell-cycle kinetics. 
In yeast, TopoII SUMO modification is not 
required for efficient chromatid disjunc-
tion (Bachant et al., 2002) and is largely, 
but not completely, dispensable for chro-
mosome segregation (Takahashi et al., 
2006). One phenotype observed in yeast 
SUMO-resistant top2 mutants, however, 
is a failure to maintain CEN compaction 
under tension as chromatids biorient on 
the spindle (Bachant et al., 2002). Could 
TopoII be mediating additional functions 
within CEN chromatin, and might these 
activities, rather than decatenation, be 
influencing the SAC? The newfound con-
nections between TopoII, SUMO, CENs, 
and cancer suggest the answers may 
prove interesting.
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Loss of the VHL tumor suppressor gene promotes cancer in several ways, including activation of the HIF 
transcription factors. HIF overexpression is associated with increased malignancy in many tumor types. So 
why is the spectrum of tumors associated with VHL loss restricted only to a few specific organs? In a recent 
paper in the March issue of Nature Cell Biology, Kaelin and colleagues provide a possible explanation, 
suggesting that VHL loss can also trigger senescence, a potent tumor suppressor mechanism.pVHL and HIF
von Hippel-Lindau (VHL) disease is a 
hereditary cancer syndrome character-
ized by a spectrum of benign and malig-
nant tumors including retinal heman-
giomas, cerebellar hemangioblastomas, 
pheochromocytomas, and renal cell 
carcinomas (Kaelin, 2002). Patients with VHL disease inherit a faulty allele of the 
ubiquitously expressed VHL tumor sup-
pressor gene, and emergence of pathol-
ogy in these patients follows the inacti-
vation of the remaining wild-type allele.
The gene product of VHL, pVHL, acts 
as the substrate recognition component 
of an E3 ubiquitin ligase complex (Kae-Cancer lin, 2002). While several proteins have 
been identified as pVHL-binding proteins 
that are subject to ubiquitin-mediated 
proteolysis, the best characterized puta-
tive substrates are the alpha subunits 
of the hypoxia-inducible factor (HIF1α, 
HIF2α, and HIF3α). The HIFs function 
as heterodimeric transcription factor Cell 13, April 2008 ©2008 Elsevier Inc. 295
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unstable alpha subunit and 
a stable beta subunit (called 
HIF1β or ARNT) (Semenza, 
2003). When oxygen is avail-
able, HIFα subunits are rap-
idly hydroxylated by members 
of the EglN prolyl hydroxylase 
family creating a high affinity 
pVHL binding site and subse-
quent HIFα polyubiquitylation 
and destruction (Kaelin, 2002). 
Under low oxygen conditions, 
HIFα subunits are not hydrox-
ylated, escape recognition by 
pVHL, heterodimerize with 
HIF1β, and transactivate tar-
get genes. Many of the genes 
regulated by HIF are involved 
in the adaptation to acute or 
chronic hypoxia and include 
genes involved in the uptake 
and metabolism of glucose 
(Glut-1), angiogenesis (VEGF, 
PDGF), control of extracellular pH (CA9), 
mitogenesis (TGFα), and erythropoiesis 
(erythropoietin) (Semenza, 2003).
In addition to HIF degradation, pVHL 
has been implicated to be involved in HIF-
independent cellular processes (Figure 
1). pVHL can bind to and direct the proper 
deposition of fibronectin and collagen IV 
within the extracellular matrix (Frew and 
Krek, 2007). In addition, it works to sta-
bilize microtubules and foster the main-
tenance of primary cilium. pVHL has also 
been reported to promote the stabiliza-
tion and activation of p53 in a HIF-inde-
pendent manner and, in neuronal cells, 
promote apoptosis by downregulation 
of Jun-B (Frew and Krek, 2007). While 
in all of these roles, pVHL loss would 
be predicted to be protumorigenic, the 
extent to which these functions are fully 
HIF-dependent or HIF-independent is still 
unclear (Figure 1).
VHL Loss and Senescence
Against this framework, this recent study 
by Kaelin and colleagues revealed an 
additional and rather unexpected function 
for pVHL. The authors report that pVHL 
inactivation can result in the induction of 
an unusual form of cellular senescence 
(Young et al., 2008). Cellular senescence 
is a state of irreversible growth arrest 
and an important in vivo tumor suppres-
sor mechanism (Campisi and d’Adda di 
Fagagna, 2007). Senescence has been 
reported to result from several cellular 
stresses, oncogene activation, and loss of 
certain tumor suppressor genes such as 
NF1 and PTEN (Chen et al., 2005; Cour-
tois-Cox et al., 2006). In this new work, 
the authors show that, relative to wild-
type mouse embryo fibroblasts (MEFs), 
MEFs harboring VHL inactivation showed 
increased rates of growth arrest and the 
accumulation of markers associated 
with senescence such as expression of 
senescence-associated beta-galactosi-
dae (SABG) and senescence-associated 
heterochromatic foci (SAHF). Additionally, 
when subjected to an in vitro immortaliza-
tion assay, only MEFs without VHL inac-
tivation were noted to undergo escape 
and immortalization. Surprisingly, the 
induction of senescence in the setting of 
VHL inactivation was not dependent upon 
HIF. Likewise, in wild-type MEFs neither 
hypoxia induction nor treatment with pro-
lyl hydroxylase inhibitors was sufficient to 
induce senescence. Collectively, these 
results suggest that pVHL loss affects a 
senescence program that is independent 
of its ability to downregulate HIF.
Through a variety of approaches, 
including the clever use of viral onco-
proteins, the authors demonstrated that 
the senescence associated with pVHL 
loss is not dependent upon activation of 
p16INK4a or p53, perhaps the two proteins 
most commonly associated 
with senescence. Instead, 
they showed that pVHL loss 
affected senescence through 
activation of the RB pathway in 
association with stabilization 
of p27KIP, a cyclin-dependent 
kinase inhibitor. The authors 
show that VHL inactivation led 
to decreased mRNA levels of 
Skp2, the ubiquitin ligase for 
p27KIP, and that the resulting 
accumulation of p27KIP will in 
turn lead to hypophosphory-
lated (activated) pRb. Intrigu-
ingly, the authors also noted 
that a mutant form of the viral 
oncoprotein adenovirus E1A 
unable to bind and inhibit 
pRb was still able to prevent 
senescence, implying that 
an additional target of E1A 
played a role in the senes-
cence of VHL-defective cells. 
Armed with the knowledge that p400, a 
SWI2/SNF2 chromatin remodeling fam-
ily member, is stabilized by E1A and 
that downregulation of p400 can induce 
senescence in human cells, the authors 
then turned to investigating the relation-
ship between pVHL and p400 (Chan 
et al., 2005; Fuchs et al., 2001). pVHL 
inactivation resulted in diminished lev-
els of p400 and the induction of senes-
cence in a p27KIP and pRb-dependent 
manner (Figure 1). These experiments 
suggest the model that in MEFs, acute 
loss of pVHL can activate senescence 
by decreasing levels of p400 with sub-
sequent activation of pRb (Figure 1). 
Finally, in accordance with this model, 
the authors demonstrate that acute 
somatic inactivation of VHL, in vivo in the 
murine kidney, is sufficient to upregulate 
levels of p27KIP and induce SABG as well 
as other markers of senescence.
The authors suggest that this interest-
ing link between pVHL loss and senes-
cence may explain the tissue specificity 
of VHL-associated disease. It is possible 
that in most tissues, loss of VHL induces 
senescence and is, therefore, not asso-
ciated with cancer, while in other tissues 
(e.g., certain kidney cells), the oncogenic 
effects of VHL loss are more potent than 
the senescence promoting effects. In 
these tissues, pVHL inactivation is most 
likely to produce neoplasia.
figure 1. pVHL Inactivation Results in Both Pro- and Antitumor-
genic effects
pVHL loss induces both oncogenic signals and tumor suppressive responses. 
Oncogenic sequelae of pVHL inactivation include Jun-B-dependent inhibition 
of neuronal apoptosis, destabilization of microtubules, defective assembly of 
the extracellular matrix (ECM), p53 inactivation, and the upregulation of HIF. 
HIF stabilization results in the transactivation of protumorigenic genes includ-
ing VEGF, PDGF, and TGFα. Kaelin and colleagues now show that pVHL loss 
also suppresses p400, resulting in p27KIP and pRb activation and promotion 
of the tumor suppressive response, cellular senescence.296 Cancer Cell 13, April 2008 ©2008 Elsevier Inc.
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This study by Kaelin and colleagues sug-
gests that, like PTEN loss or RAS activa-
tion, an oncogenic event such as VHL 
inactivation can also induce tumor sup-
pression via induction of cellular senes-
cence in certain contexts. This finding 
raises several additional questions. First, 
although not HIF-dependent, exactly how 
pVHL plays a role in maintaining p400 
expression is not clear. Whether this 
involves one of the known HIF-indepen-
dent biochemical activities of pVHL (Fig-
ure 1) or a novel mechanism remains to 
be determined. Also, there appears to be 
a difference in the effects of pVHL loss 
in human and murine cells. While Kaelin 
and colleagues evidenced that pVHL loss 
results in decreased p400 expression in 
MEFs, they do not note this relationship 
in human cells. Indeed, in human diploid 
fibroblasts, either HIFα expression or 
pVHL loss appears to bypass senescence 
through the induction of telomerase (Bell 
et al., 2007). It is not readily clear how to 
reconcile these findings, although they 
may reflect species or cell type differ-
ences in the response to pVHL loss.
Lastly, in our view, telomere-indepen-
dent senescence remains an enigma. 
While critical for day-to-day tumor sup-
pression in mammals, their stimuli and 
precise effector pathways are only par-tially understood. Several stimuli relat-
ing to cellular metabolism (excess AKT/
RAS signaling, oxidative stress, and 
pVHL loss in the present work among 
others) have now been shown to facili-
tate cellular senescence. While it is pos-
sible that these different events share a 
common promoting feature and path-
way to senescence (e.g., DNA damage), 
it is equally plausible that they represent 
different flavors of senescence, induced 
by independent modes of stimuli asso-
ciated with neoplasia.
The present work would appear most 
consistent with the latter possibility, 
which is a senescence mechanism that 
appears to occur independently of p53 
and p16INK4a activation but relies on p27KIP 
stabilization. Moreover, senescence 
associated with pVHL loss does not seem 
to entail a DNA damage response, and in 
these ways, this senescence induced by 
pVHL inactivation in MEFs appears quite 
different from that induced by RAS acti-
vation or ionizing radiation in human dip-
loid fibroblasts (Campisi and d’Adda di 
Fagagna, 2007). Nonetheless, these dif-
ferent stimuli all produce a growth arrest 
that bears the experimental hallmarks 
of senescence (SAHF and SABG). One 
continues to hope that determining how 
these seemingly unrelated genetic events 
converge to produce the common end Cancerpoint of cellular senescence might allow 
this most potent anticancer mechanism 
to be harnessed for the therapy of estab-
lished cancers.
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